Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksandra Marciniak has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Interactions of Bioactive Peptides with Proteins and DNA

    by Aleksandra Kotynia, Edward Krzyżak, Żaneta Czyżnikowska, Aleksandra Marciniak

    Background: This study investigates the molecular recognition of two biologically active peptides (P1 and P2) by key biomacromolecular targets. The studied peptides were previously identified in Babylon snail hydrolysates and have been shown to exhibit antioxidant and cytotoxic activities against Caco-2 colorectal cancer cells. Given their reported biological potential, we decided to investigate both compounds from a different perspective. Their interactions with human serum albumin (HSA), alpha-1-acid glycoprotein (AAG), lysozyme (LYS), immunoglobulin G (IgG), and DNA were evaluated. Methods, Results and Conclusions: Spectroscopic analyses revealed concentration-dependent binding of the studied peptides to plasma proteins under investigations. Notably, peptide binding did not substantially alter the secondary structure of the target proteins, indicating that complex formation occurs without significant structural perturbation. Molecular docking further supported the formation of peptide–protein complexes, highlighting the contribution of hydrogen bonding and hydrophobic contacts to molecular recognition. The combined spectroscopic and docking results were consistent with a predominantly non-intercalative, possibly minor-groove-associated interaction with ctDNA. Taken together, these findings provide a comparative physicochemical characterization of the interactions of P1 and P2 with selected proteins and ctDNA. These findings provide insight into the molecular recognition properties of P1 and P2 and support further investigation of their biological relevance.

  • Open Access

    The Chelating Abilities of Tertiary Amines with N-O-Donors Towards Cu(II) Ions and the Catalytic Properties of the Resulting Complexes

    by Martina Zonzin, Martina Chianese, Andrea Squarcina, Degnet Melese Dereje, Ambra Campofelice, Alessia Da Fermo, Federica Belluti, Nadia Marino, Filip Dębicki, Aleksandra Kotynia, et al.

    Oxidative stress, driven by excess reactive oxygen species (ROS), is a key factor in the progression of neurodegenerative diseases like Alzheimer’s disease (AD). In this context, copper dysregulation can also contribute to this imbalance, being responsible for enhanced ROS production, so that copper scavenging has been investigated as a possible therapeutic strategy. This study investigates the behavior of two isostructural ligands, featuring an N3O donor set, that effectively chelate Cu(II) in aqueous solution. Interestingly, their resulting mono- or dinuclear copper complexes feature a coordination environment suitable to foster antioxidant activity. By transforming copper’s oxidant potential into antioxidant action, these systems may reduce copper-induced oxidative damage. The work examines the pH-dependent metal-binding behavior of the ligands, the catalytic properties of the resulting complexes under physiological conditions, and their ability to inhibit β-amyloid peptide aggregation.


  • Open Access

    In Silico Approach to Design of New Multi-Targeted Inhibitors Based on Quinoline Ring with Potential Anticancer Properties

    by Żaneta Czyżnikowska, Martyna Mysłek, Aleksandra Marciniak, Remigiusz Płaczek, Aleksandra Kotynia, Edward Krzyżak

    Searching for new anticancer drugs is a significant challenge for the medical community due to the current limitations of existing treatments. The primary objective of this study was to design and optimize multi-targeted drug candidates based on a quinoline scaffold. In this paper, we adopt various in silico techniques, including molecular docking, molecular dynamics simulations, and ADMET property modeling, to predict the binding affinity and interactions of 7-ethyl-10-hydroxycamptothecin derivatives with multiple biological targets. The interactions of these compounds with three potential molecular targets, topoisomerase I, bromodomain-containing protein 4, and ATP-binding cassette sub-family G member 2 proteins, were analyzed. It has been previously proved that the inhibition of these molecular targets may have beneficial effects on cancer treatment. The designed chemical compounds can effectively interact with selected proteins, thereby establishing their potential as drug candidates. Molecular docking revealed promising binding affinities, with topoisomerase I docking scores ranging from −9.0 to −10.3 kcal/mol, BRD4 scores from −6.6 to −8.0 kcal/mol, and ABCG2 scores from −8.0 to −10.0 kcal/mol. Furthermore, the ADMET property analysis indicates promising pharmacological profiles, protein binding affinity, selectivity, and bioavailability while minimizing toxicity. For example, satisfactory logP values have been demonstrated in the favorable range for bioavailability after oral administration. Additionally, several compounds exhibited predicted aqueous solubility values greater than −3, suggesting moderate-to-good solubility, which is crucial for oral drug delivery.


  • Open Access

    A Spectroscopic and In Silico Description of the Non-Covalent Interactions of Phthalic Acid Imide Derivatives with Deoxyribonucleic Acid—Insights into Their Binding Characteristics and Potential Applications

    by Aleksandra Marciniak, Edward Krzyżak, Dominika Szkatuła, Krystian Mazurkiewicz, Aleksandra Kotynia

    The treatment of cancer represents one of the most significant challenges currently facing modern medicine. The search for new drugs that are effective in the treatment of patients is an ongoing endeavor. It is frequently the case that the molecular target of anticancer drugs is a DNA molecule. The therapeutic effect of a drug is achieved by influencing the structure of a macromolecule or by inhibiting its function. Among the synthetic substances with potential anticancer effects, particular attention should be paid to phthalic acid imide derivatives. Three phthalimide derivatives are employed in the treatment of multiple myeloma: thalidomide, pomalidomide, and lenalidomide. Nevertheless, the search for new derivatives with a diverse range of biological activities is ongoing. In light of the above, the subject of our investigation is four non-toxic phthalic acid imide derivatives. The objective was to analyze the interaction of these compounds with DNA. The use of spectroscopic and in silico methods has enabled us to demonstrate that all of the tested analogs can act as ligands for deoxyribonucleic acid, forming non-covalent bonds with it. All four compounds tested interact with the ctDNA molecule, binding in its minor groove. The most stable complex is formed here between deoxyribonucleic acid and the C derivative, in which the -CF3 group is attached to the benzene ring. What is interesting and important, the described mechanism of action is analogous to that observed between ctDNA and thalidomide, pomalidomide, and lenalidomide.


  • Open Access

    A Series of Novel 1-H-isoindole-1,3(2H)-dione Derivatives as Acetylcholinesterase and Butyrylcholinesterase Inhibitors: In Silico, Synthesis and In Vitro Studies

    by Edward Krzyżak, Aleksandra Marciniak, Dominika Szkatuła, Klaudia A. Jankowska, Natalia Dobies, Aleksandra Kotynia

    The derivatives of isoindoline-1,3-dione are interesting due to their biological activities, such as anti-inflammatory and antibacterial effects. Several series have been designed and evaluated for Alzheimer’s therapy candidates. They showed promising activity. In this work, six new derivatives were first tested in in silico studies for their inhibitory ability against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes. Molecular docking and molecular dynamic simulation were applied. Next, these compounds were synthesized and characterized by 1H NMR, 13C NMR, FT-IR, and ESI–MS techniques. For all imides, the inhibitory activity against AChE and BuChE was tested using Ellaman’s method. IC50 values were determined. The best results were obtained for the derivative I, with a phenyl substituent at position 4 of piperazine, IC50 = 1.12 μM (AChE) and for the derivative III, with a diphenylmethyl moiety, with IC50 = 21.24 μM (BuChE). The compounds tested in this work provide a solid basis for further structural modifications, leading to the effective design of potential inhibitors of both cholinesterases.


  • Open Access

    Protopine and Allocryptopine Interactions with Plasma Proteins

    by Aleksandra Marciniak, Aleksandra Kotynia, Edward Krzyżak, Żaneta Czyżnikowska, Sylwia Zielińska, Weronika Kozłowska, Marcel Białas, Adam Matkowski, Anna Jezierska-Domaradzka

    A comprehensive study of the interactions of human serum albumin (HSA) and α-1-acid glycoprotein (AAG) with two isoquinoline alkaloids, i.e., allocryptopine (ACP) and protopine (PP), was performed. The UV-Vis spectroscopy, molecular docking, competitive binding assays, and circular dichroism (CD) spectroscopy were used for the investigations. The results showed that ACP and PP form spontaneous and stable complexes with HSA and AAG, with ACP displaying a stronger affinity towards both proteins. Molecular docking studies revealed the preferential binding of ACP and PP to specific sites within HSA, with site 2 (IIIA) being identified as the favored location for both alkaloids. This was supported by competitive binding assays using markers specific to HSA’s drug binding sites. Similarly, for AAG, a decrease in fluorescence intensity upon addition of the alkaloids to AAG/quinaldine red (QR) complexes indicated the replacement of the marker by the alkaloids, with ACP showing a greater extent of replacement than PP. CD spectroscopy showed that the proteins’ structures remained largely unchanged, suggesting that the formation of complexes did not significantly perturb the overall spatial configuration of these macromolecules. These findings are crucial for advancing the knowledge on the natural product–protein interactions and the future design of isoquinoline alkaloid-based therapeutics.


  • Open Access

    The Role of the Unbinding Cycle on the Coordination Abilities of the Bi-Cyclopeptides toward Cu(II) Ions

    by Alicja Lisowska, Paulina Świątek, Filip Dębicki, Agnieszka Lewińska, Aleksandra Marciniak, Lorenzo Pacini, Anna Maria Papini, Justyna Brasuń

    Bicyclic peptides have attracted the interest of pharmaceutical companies because of their remarkable properties, putting them on a new path in medicine. Their conformational rigidity improves proteolytic stability and leads to rapid penetration into tissues via any possible route of administration. Moreover, elimination of renal metabolism is of great importance, for example, for people with a history of liver diseases. In addition, each ring can function independently, making bicyclic peptides extremely versatile molecules for further optimization. In this paper, we compared the potentiometric and spectroscopic properties studied by UV–vis, MCD, and EPR of four synthetic analogues of the bi-cyclic peptide c(PKKHP-c(CFWKTC)-PKKH) (BCL). In particular, we correlated the structural and spectral properties of complexes with coordinating abilities toward Cu(II) ions of MCL1 (Ac-PKKHPc(CFWKTC)PKKH-NH2) that contains the unbinding cycle and N- and C-terminal linear parts with two histidine residues, one per part; two monocyclic ligands containing one histidine residue, both in the N-terminal position, i.e., MCL2 (Ac-PKKHPc(CFWKTC)PKKS-NH2) and in the C-terminal position, i.e., MCL3 (Ac-PKKSPc(CFWKTC)PKKH-NH2), respectively; and the linear structure LNL (Ac-PKKHPSFWKTSPKKH-NH2). Potentiometric results have shown that the bicyclic structure promotes the involvement of the side chain imidazole donors in Cu(II) binding. On the other hand, the results obtained for the mono-cyclic analogues lead to the conclusion that the coordination of the histidine moiety as an anchoring group is promoted by its location in the peptide sequence further from the nonbinding cycle, strongly influencing the involvement of the amide donors in Cu(II) coordination.

  • Open Access

    Isoquinoline Alkaloids Interaction With Plasma Proteins

    by Aleksandra Marciniak, Aleksandra Kotynia, Edward Krzyżak, Żaneta Czyżnikowska, Sylwia Zielińska, Weronika Kozłowska, Marcel Białas, Adam Matkowski, Anna Jezierska-Domaradzka

    A comprehensive study of the interactions of human serum albumin (HSA) and α-1-acid glycoprotein (AAG) with two isoquinoline alkaloids: allocryptopine (ACP) and protopine (PP) was performed. The UV-Vis spectroscopy, molecular docking, competitive binding assays, and circular dichroism (CD) spectroscopy were used for the investigations. The results showed that ACP and PP form spontaneous and stable complexes with HSA and AAG, with ACP displaying a stronger affinity towards both proteins. Molecular docking studies showed also revealed the preferential binding of ACP and PP to specific sites within HSA, with site 2 (IIIA) being identified as the favored location for both alkaloids. This was supported by competitive binding assays using markers specific to HSA's drug binding sites. Similarly, for AAG, a decrease in fluorescence intensity upon addition of the alkaloids to AAG/ Quinaldine Red (QR) complexes indicated the replacement of the marker by the alkaloids, with ACP showing a greater extent of replacement than PP. CD spectroscopy showed that the proteins’ structures remained largely unchanged suggesting that the formation of complexes did not significantly perturb the overall spatial configuration of these macromolecules. These findings are crucial for advancing the knowledge on the natural products-protein interactions and the future design of isoquinoline alkaloid-based therapeutics.

  • Open Access

    The Role of the Unbinding Cycle on the Coordination Abilities of the Bi-Cyclopeptides Toward Cu(II) Ions

    by Alicja Lisowska, Paulina Swiatek, Filip Debicki, Agniezska Lewinska, Aleksandra Marciniak, Lorenzo Pacini, Anna Maria Papini, Justyna Brasun

    Bicyclic peptides have attracted the interest of pharmaceutical companies because of their remarkable properties putting them on a new path in medicine. Their conformational rigidity that improves proteolytic stability, leads to rapid penetration into tissues via any possible route of administration and elimination, occurring by renal metabolism, is of great importance for people with a history of liver diseases. In addition, each ring can function independently, making them extremely versatile molecules for further optimization. In this paper we compared the potentiometric and spectroscopic properties studied by UV-Vis, MCD, and EPR, of four synthetic analogues of the bi-cyclic peptide c(PKKHP-c(CFWKTC)-PKKH). In particular we correlated the structural and spectral properties of complexes with coordinating abilities toward Cu(II) ions of MCL (Ac-PKKHPc(CFWKTC)PKKH-NH2) that contains the unbinding cycle and N- and C-terminal linear parts, with two histidine residues, one per part; two monocyclic ligands containing one histidine residue, both in the N-terminal position i.e., MCL2 (Ac-PKKHPc(CFWKTC)PKKS-NH2) and in the C-terminal position i.e., MCL3 (Ac-PKKSPc(CFWKTC)PKKH-NH2), respectively, and the linear structure LNL (Ac-PKKHPSFWKTSPKKH-NH2).

  • Open Access

    Anti-Inflammatory and Antioxidant Pyrrolo[3,4-d]pyridazinone Derivatives Interact with DNA and Bind to Plasma Proteins—Spectroscopic and In Silico Studies

    by Aleksandra Kotynia, Edward Krzyżak, Julia Żądło, Maja Witczak, Łukasz Szczukowski, Jakub Mucha, Piotr Świątek, Aleksandra Marciniak

    From the point of view of the search for new pharmaceuticals, pyridazinone derivatives are a very promising group of compounds. In our previous works, we have proved that newly synthesized ligands from this group have desirable biological and pharmacokinetic properties. Therefore, we decided to continue the research evaluating the activity of pyrrolo[3,4-dpyridazinone derivatives. In this work, we focused on the interactions of five pyridazinone derivatives with the following biomolecules: DNA and two plasma proteins: orosomucoid and gamma globulin. Using several of spectroscopic methods, such as UV-Vis, CD, and fluorescence spectroscopy, we proved that the tested compounds form stable complexes with all biomacromolecules selected for analysis. These findings were also confirmed by the results obtained by molecular modeling. All tested pyridazinone derivatives bind to the ctDNA molecule via groove binding mechanisms. All these molecules can also be bound and transported by the tested plasma proteins; however, the stability of the complexes formed is lower than those formed with serum albumin.